It's not every day a company attempts a do-over on a previously-failed clinical program but that's exactly what Medtronic (Dublin, Ireland) appears to be doing with renal denervation for uncontrolled hypertension. The company has initiated a new program, dubbed SPYRAL HTN, that will include two global studies designed to address the confounding factors encountered in its SYMPLICITY HTN-3 trial, including medication, patient population, and procedural variability. Read More
